The FDA has approved ramipril for the reduction of cardiovascular risk, including myocardial infarction, stroke, and cardiovascular death.
Answers are grounded in this paper and cite their sources.
FDA approval expands ramipril use for CV risk reduction; leaves open optimal selection and long-term outcomes in routine practice.
The FDA has approved labeling for a new use for the antihypertensive drug ramipril (Altace, Aventis Pharmaceuticals, Kansas City, Mo), an ACE inhibitor, to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes.
No takes yet. Share an insight, caveat, or question.
Jane E. Henney (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: